Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2015—BBCS received 510(k) clearance for its ABO Wheels, a blood bank software solution that is part of the company’s ABO Suite. ABO Wheels is a mobile blood-collection application that allows blood centers to conduct paperless donor registration and screening at either a collection facility or a non-fixed site, regardless of connectivity to the main database.
March 2015—The CE-IVD Oncomine Solid Tumor DNA kit from Thermo Fisher Scientific enables accurate and reliable multiplexed sequencing of formalin-fixed, paraffin-embedded tumor. Based on the Ion Torrent AmpliSeq technology, the kit allows detection of single nucleotide somatic changes, inversions, insertions, and deletions using as little as 10 ng of FFPE DNA …
March 2015—The Compass Group has awarded Visiun a sole-source agreement for business intelligence software for Compass Group’s 26 nonprofit health systems.
March 2015—Transworld Systems, a cash-flow management and profit recovery company, announced a dedicated division to work with medical laboratories. Profit Recovery and Profit Recovery Plus are flat-fee, automated collection systems that generate diplomatic, written demands from a third party. According to the company, flat-fee written contacts are getting outstanding results in the low-balance, high-volume environment laboratories create. The initiative is headed by Michael Paro, accounts receivable advisory specialist for medical labs.
March 2014—The Food and Drug Administration cleared a screening test that predicts a patient’s risk of future coronary heart disease events, such as heart attacks. The test is cleared for use in all adults with no history of heart disease, but studies submitted by the company and reviewed by the FDA show that the test is better at discerning this risk in women, particularly black women.
March 2014—The BioFlo 320 from Eppendorf is built with integrated control for both autoclavable and single-use vessels with a total working volume of 250 mL to 40 L on a single control platform. Ethernet communication connects up to eight systems from a single user interface for multi-unit control, and the Mettler-Toledo Intelligent Sensor Management platform is built into the system.
March 2014—The Clinical and Laboratory Standards Institute has published a new document, “Planning for Laboratory Operations During a Disaster; Approved Guideline (GP36-A).” The document provides guidance for laboratory and health care leadership for development, implementation, and sustainment of effective emergency preparedness plans (all hazards) supporting nonanalytical components of clinical and public health laboratory services that may pertain to various natural and manmade disasters.
March 2014—The Ativa microlab from Ativa Medical is a point-of-care device designed to perform the most common blood-based tests in a clinical setting in five minutes. The system requires only a few drops of blood and runs on a disposable microfluidic card.
March 2014—The Diagnostics Division of Siemens Healthcare is unveiling its latest point-of-care acute care analyzer for the management of patients with cardiovascular disease symptoms. The company’s Stratus CS 200 Acute Care Diagnostic System is designed for simple operation and instrument management at the point of care to help facilitate rapid decision-making and provide optimal patient care.
March 2014—Quest Diagnostics will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis, and treatment for four strains of viral hepatitis in the U.S. Under terms of the multiyear contract, Quest will provide CDC researchers with analytics expertise and access to the company’s national Health Trends database of de-identified clinical testing hepatitis data.
